Cancer, Early-line clear cell renal cell carcinoma (ccRCC)
RCUSArcus BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Casdatifan (AB521) (HIF-2a Inhibitor) in Cancer, Early-line clear cell renal cell carcinoma (ccRCC). The expected timing is based on the latest available company guidance and may change.
ARC-20 early-line cohorts. 12/12/25:- Initial data from early-line casdatifan cohorts in H2 2026 and potential additional study initiations. 02/25/26:- ARC-20 early-line ccRCC: zimberelimab+ipilimumab cohort enrolling; zimberelimab cohort fully enrolled; H2 2026 data planned. 05/05/26:- ARC-20 early-line: casdatifan+zimberelimab cohort fully enrolled; zimberelimab+ipilimumab cohort enrolling; initial early-line data planned for 2026. 08/05/26:- ARC-20 first-line efficacy and safety data expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.